Industry top-down
Diagnostics & Research
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
AI industry top-down
The Diagnostics and Research industry showed overall moderate growth during FY2026 Q1, recording a median revenue growth rate of 5.4%. While some companies, such as Natera and Adaptive Biotechnologies, achieved high, double-digit revenue growth, major players like Danaher, Illumina, and Charles River experienced revenue declines. Furthermore, many companies showed negative growth in earnings per share (EPS), highlighting a gap between revenue growth and profitability. Overall, the industry presents a complex mix of both growth and contraction.
- Industry revenue growth rate shows a moderate increase of 5.4%
- Some companies recorded double-digit revenue growth
- Negative EPS growth for many companies
- Sluggish revenue and EPS performance for major large companies
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| TMOTHERMO FISHER SCIENTIFIC INC. | FY2026 Q2 | $11.99B | +10.5% | $4.68 | +9.3% | — |
| DHRDANAHER CORP /DE/ | FY2026 Q2 | $6.27B | +5.5% | $1.23 | +59.7% | — |
| NTRANatera, Inc. | FY2026 Q2 | $752.75M | +37.7% | $-0.47 | — | — |
| AAGILENT TECHNOLOGIES, INC. | FY2026 Q3 | $1.88B | +8.1% | $1.28 | +8.5% | — |
| IQVIQVIA HOLDINGS INC. | FY2026 Q1 | $4.15B | +8.4% | $1.61 | +15.0% | — |
| WATWATERS CORP /DE/ | FY2026 Q2 | $1.65B | +113.3% | $-1.39 | — | — |
| IDXXIDEXX LABORATORIES INC /DE | FY2026 Q2 | $1.22B | +9.7% | $4.27 | +17.6% | — |
| ILMNILLUMINA, INC. | FY2026 Q2 | $1.16B | +9.4% | $1.35 | -9.4% | — |
| MTDMETTLER TOLEDO INTERNATIONAL INC/ | FY2026 Q2 | $1.03B | +4.5% | $11.55 | +18.3% | — |
| DGXQUEST DIAGNOSTICS INC | FY2026 Q2 | $3.04B | +10.2% | $2.84 | +15.0% | — |
| LHLABCORP HOLDINGS INC. | FY2026 Q2 | $3.73B | +5.8% | $3.64 | +28.2% | — |
| GHGuardant Health, Inc. | FY2026 Q2 | $334.98M | +44.3% | $-0.90 | — | — |
| MEDPMedpace Holdings, Inc. | FY2026 Q2 | $707.33M | +17.2% | $4.25 | +37.1% | — |
| RVTYREVVITY, INC. | FY2026 Q2 | $729.69M | +1.3% | $0.47 | +2.2% | — |
| CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC. | FY2026 Q2 | $1B | -2.7% | $-0.03 | — | — |
| ICLRICON PLC | FY2026 Q2 | $2.06B | +2.3% | $0.94 | -59.1% | — |
| BLLNBillionToOne, Inc. | FY2026 Q2 | $109.45M | — | $0.15 | — | — |
| GRALGRAIL, Inc. | FY2026 Q2 | $44.69M | +25.7% | $-2.56 | — | — |
| RDNTRadNet, Inc. | FY2026 Q2 | $622.72M | +25.0% | $0.10 | -47.4% | — |
| SHCSotera Health Co | FY2026 Q2 | $321.38M | +9.2% | $0.19 | — | — |
| ADPTAdaptive Biotechnologies Corp | FY2026 Q2 | $71.55M | +21.5% | $-0.25 | — | — |
| VCYTVERACYTE, INC. | FY2026 Q2 | $150.32M | +15.5% | $0.31 | — | — |
| CDNACareDx, Inc. | FY2026 Q2 | $131.95M | +52.2% | $2.07 | — | — |
| WGSGeneDx Holdings Corp. | FY2026 Q2 | $114.44M | +11.4% | $-0.60 | — | — |
| PSNLPersonalis, Inc. | FY2026 Q2 | $22.36M | +30.0% | $-0.30 | — | — |
| OPKOPKO HEALTH, INC. | FY2026 Q2 | $163.58M | +4.3% | $-0.01 | — | — |
| CSTLCASTLE BIOSCIENCES INC | FY2026 Q2 | $103.55M | +20.1% | $-0.07 | — | — |
| MYGNMYRIAD GENETICS INC | FY2026 Q2 | $190.7M | -10.5% | $-0.46 | — | — |
| BDSXBIODESIX INC | FY2026 Q2 | $26.86M | +34.2% | $-0.71 | — | — |
| XGNEXAGEN INC. | FY2026 Q2 | $19.94M | +15.9% | $-0.13 | — | — |
| 144510GC CELL CORPORATION | FY2026 Q2 | ₩41.6B | -3.1% | ₩157.00 | — | — |
| IMDXInsight Molecular Diagnostics Inc. | FY2026 Q2 | $239K | -53.9% | $-0.31 | — | — |
| FONRFONAR CORP | FY2023 Q3 | $72.78M | — | $1.43 | — | — |
| 051980JOONGANG ADVANCED MATERIALS Co., Ltd | FY2026 Q1 | ₩2.33B | -30.4% | ₩-0.87 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).